Press Releases Q32 Bio Inc.

Equities

QTTB

US7469641051

Market Closed - Nasdaq Other stock markets 02:00:00 07/05/2024 am IST			5-day change	1st Jan Change
25.85 ^USD	+1.02%		-10.98%	+133.83%

11/04	Oppenheimer Initiates Coverage on Q32 Bio With Outperform Rating, $50 Price Target	MT
03/04	Q32 Bio Inc. Appoints Lee Kalowski as Chief Financial Officer	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer	03/04	PR
Homology Medicines Declares Distribution to Common Stockholders	19/03	AQ
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX	28/02	BU
Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency	04/01	AQ
HOMOLOGY MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Homology Medicines, Inc. - FIXX	18/11	BU
FIXX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Homology Medicines, Inc. Is Fair to Shareholders	16/11	BU
Q32 Bio and Homology Medicines Announce Merger Agreement	16/11	PR
Q32 Bio and Homology Medicines Announce Merger Agreement	16/11	AQ
Homology Medicines: Q3 Earnings Snapshot	15/11	AQ
Homology Medicines Reports Third Quarter 2023 Financial Results	15/11	AQ
Metachromatic Leukodystrophy Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)	09/23/09	AQ
Kaskela Law LLC Announces Investigation of Homology Medicines, Inc. (NASDAQ: FIXX) and Encourages Long-Term Investors to Contact the Firm - FIXX	16/23/16	PR
Homology Medicines: Q2 Earnings Snapshot	15/23/15	AQ
Homology Medicines Reports Second Quarter 2023 Financial Results and Recent Highlights	15/23/15	AQ
Homology Medicines : Costs Associated with Exit/Disposal - Form 8-K	30/23/30	PU
Homology Medicines : Corporate Presentation - July 2023	28/23/28	PU
Homology Medicines Announces Plan to Evaluate Strategic Options for the Company and its Genetic Medicines Programs, including HMI-103 Gene Editing Candidate for PKU	28/23/28	AQ
Homology Medicines Announces Encouraging Initial Data from First Dose Level in the pheEDIT Trial Evaluating Gene Editing Candidate HMI-103 in Adults with Classical PKU	28/23/28	AQ
Homology Medicines : Corporate Presentation - June 2023	16/23/16	PU
HOMOLOGY MEDICINES, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	15/23/15	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Q32 Bio Inc.

Equities

QTTB

US7469641051

Press Releases

Filters